Orthofix Q1 FY26 net loss narrows to $20.9 million; net sales rise 1.6% to $196.7 million

Orthofix Medical, Inc.

Orthofix Medical, Inc.

OFIX

0.00
  • Orthofix posted first-quarter net loss of USD 20.9 million, narrowing from prior-year loss of USD 53.1 million; loss per share improved to USD 0.52.
  • Net sales rose 1.6% to USD 196.7 million.
  • Gross margin was 70.9%.
  • Cash, cash equivalents, and restricted cash climbed to USD 120.9 million from USD 85.1 million at Dec. 31, 2025, on financing activities during the quarter.
  • Full-year 2026 outlook was reaffirmed, with net sales seen at USD 850 million to USD 860 million and non-GAAP adjusted EBITDA at USD 95 million to USD 98 million.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Orthofix Medical Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260505284891) on May 05, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.